Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Mallinckrodt

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Mallinckrodt's Japan sales performance.

Mallinckrodt

Deal Watch table for April 2014

Deal Watch table for April 2014 7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

Mallinckrodt cuts $5.6bn deal to buy Questcor

Mallinckrodt cuts $5.6bn deal to buy Questcor Under the terms of the deal, Questcor's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share they own. ... Mallinckrodt investors seemed to be wary of the deal, however, and the Irish firm's share price went on the slide

Mallinckrodt offers $1.3bn for Cadence Pharma

Deal would include injectable painkiller Ofirmev. Irish pharma company Mallinckrodt has agreed a $1.3bn deal to buy US biotech Cadence Pharmaceuticals and its fast-growing injectable painkiller Ofirmev. ... Mallinckrodt's offer comes shortly after

FDA grants priority review to pain drug

Mallinckrodt’s MNK-795 is intended for the management of moderate to severe acute pain. ... The drug was originally developed using technology from Depomed, which signed a license agreement with Mallinckrodt.

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer Other previous positions include senior VP commercial operations at pain specialists Alpharma Pharmaceuticals, VP marketing at Endo Pharmaceuticals and VP global strategy and commercial development at Mallinckrodt.

[ Previous 5 results ] 1 2 3 4 5 6 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics